DDT

Dillard's Capital Trust I

Bullish Trend

Near 52W High

Volume Surge

$26.30$0.06 (-0.21%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Key Statistics

Forward P/E—

52-Week Return+1.58%

50-Day Moving Avg$26.28

200-Day Moving Avg$26.16

Volume Today18.16K

Avg Volume8.17K

Day Range$26.12 – $26.39

52-Week Range$25.11 – $26.80

Open Price$26.40

Previous Close$26.36

Company Profile

No profile description available.

Exchange Listing

DDT

Key Statistics

Company Profile

Company Profile

Recent News

Recent News

Company Profile

Recent News

DDT

Key Statistics

Company Profile

Company Profile

Recent News

Today in history, August 29

Delta Development Team's DoW Cold Chain Logistics Solution Assessed "Awardable" in Tradewinds Solutions Marketplace

DATAMARK Technologies, a Michael Baker International Company, Announces Three New Partnerships to Drive Public Safety Innovation

BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026

Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

Forward Blood Is Not a Medical Problem. It's a Logistics Problem.

Advancing Prehospital Care in Texas: Delta Development Team Supporting the State's $10 Million Whole Blood Initiative

Absentia Labs' Digital Liver Model Becomes First AI Drug Development Tool Accepted Into FDA Qualification Program

Recent News

Company Profile

Recent News

Today in history, August 29

Delta Development Team's DoW Cold Chain Logistics Solution Assessed "Awardable" in Tradewinds Solutions Marketplace

DATAMARK Technologies, a Michael Baker International Company, Announces Three New Partnerships to Drive Public Safety Innovation

BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026

Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

Forward Blood Is Not a Medical Problem. It's a Logistics Problem.

Advancing Prehospital Care in Texas: Delta Development Team Supporting the State's $10 Million Whole Blood Initiative

Absentia Labs' Digital Liver Model Becomes First AI Drug Development Tool Accepted Into FDA Qualification Program